STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer
- Journal: Journal for ImmunoTherapy of Cancer, January 2023
- Authors: Ding L, Wang Q, Martincuks A, Kearns MJ, Jiang T, Lin Z, Cheng X, Qian C, Xie S, Kim HJ, Launonen IM, Färkkilä A, Roberts TM, Freeman GJ, Liu JF, Konstantinopoulos PA, Matulonis U, Yu H, Zhao JJ.
- Citation: J Immunother Cancer. 2023 Jan;11(1):e005627. doi: 10.1136/jitc-2022-005627.
EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis
- Journal: The EMBO Journal, March 2019
- Authors: Zhao Y, Ding L, Wang D, Ye Z, He Y, Ma L, Zhu R, Pan Y, Wu Q, Pang K, Hou X, Weroha SJ, Han C, Coleman R, Coleman I, Karnes RJ, Zhang J, Nelson PS, Wang L, Huang H.
- Citation: EMBO J. 2019 Mar 1;38(5):e99599. doi: 10.15252/embj.201899599.
PARP inhibition elicits STING-dependent antitumor immunity in BRCA1-deficient ovarian cancer
- Journal: Cell Reports, December 2018
- Authors: Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ.
- Citation: Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054.
CBP loss cooperates with PTEN haploinsufficiency to drive prostate cancer: implications for epigenetic therapy
- Journal: Cancer Research, April 2014
- Authors: Ding L, Chen S, Liu P, Pan Y, Zhong J, Regan KM, Wang L, Yu C, Rizzardi A, Cheng L, Zhang J, Schmechel SC, Cheville JC, Van Deursen J, Tindall DJ, Huang H.
- Citation: Cancer Res. 2014 Apr 1;74(7):2050-61. doi: 10.1158/0008-5472.CAN-13-1659.
Connect with the Ding Lab
Email: Liya.Ding@RoswellPark.org
Office location: Center for Genetics & Pharmacology (CGP) L5-310
Lab Location: Center for Genetics & Pharmacology (CGP) L5-111
Department of Immunology
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263